Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

NCT03116516 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Hyperlipidemia

Interventions

DRUG: Temisartan/Amlodipine+Rosuvastatin
DRUG: YHP1604

Sponsor

Yuhan Corporation